Medincell (LTS:0ACH) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0ACH Medincell SA LTS:0ACH
78 GF Score
Price €26.88
GF Value €21.95
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Medincell Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

LTS:0ACH
78GF Score
Medincell SA LTS:0ACH
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medincell (LTS:0ACH) Overvalued in 2026?

Based on GuruFocus' analysis, Medincell stock appears to be overvalued. The current stock price of €26.88 is trading 22.5% above its estimated GF Value™ of €21.95. GuruFocus considers Medincell to be Modestly Overvalued.

Key valuation signals for LTS:0ACH:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €21.95 vs. price of €26.88 (22.5% above fair value)
  • GF Score™: 78/100 with 5 warning signs

No single metric tells the full story. See the LTS:0ACH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medincell Business Description

Address 3 rue des Freres Lumiere, Jacou, FRA, 34830
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
78GF Score

Get the complete analysis for LTS:0ACH

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.88
Price
€21.95
GF Value